Objective: Using experimental, yet realistic, headache calendars, this laboratory study evaluated the ability of individuals to identify the degree of association between triggers and headaches.
Background: Individuals with headache often record daily diaries or calendars to identify their patterns of triggers.
Methods: This cross-sectional, observational study included adults with migraine, tension-type, or cluster headache who had ever experienced more than 5 attacks. Participants (N = 300) were presented with headache calendars and asked to rate the strength of the relationship (how strongly one causes the other) between 3 experimental triggers (high stress, poor sleep, and cinnamon) and headache using a 0 ("no relationship") to 10 ("perfect relationship") scale for each calendar.
Results: Calendars with a high positive correlation between trigger and headache had higher participant ratings than those with low correlations. The median [25th, 75th] of ratings for each correlation level was low correlation: 1 [0, 4], medium: 4 [2, 5], and high: 5 [4, 8], P < .0001. However, participants appeared to ignore negative associations (ie, trigger present with no headache) and rated calendars with more headache days as having higher associations, regardless of the true relationship. The ratings for 2, 6, and 26 headache days were 1 [0, 3], 4 [1, 6], and 8 [0, 10], respectively (P < .0001). Participants' previous beliefs about the triggers also affected their ratings (average correlation across triggers: r = 0.25, P < .0001).
Conclusions: This laboratory task supports the notion that individuals with headache are able to identify the association between headaches and triggers using headache calendars. However, these judgments can be biased by the individuals' previous beliefs about the trigger and by the degree of headache activity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077923 | PMC |
| http://dx.doi.org/10.1111/head.13703 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine.
JAMA Neurol
January 2025
Geriatric Research Education and Clinical Center, North Florida/South Georgia Veterans Health System, Gainesville, Florida.
Importance: Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP mAbs) offer effective migraine-specific preventive treatment. However, concerns exist about their potential cardiovascular risks due to CGRP blockade.
Objective: To compare the incidence of cardiovascular disease (CVD) between Medicare beneficiaries with migraine who initiated anti-CGRP-mAbs vs onabotulinumtoxinA in the US.
An objective neurophysiological study of subconcussion in female and male high school student athletes.
Sci Rep
November 2024
Atria Academy of Science and Medicine, New York City, NY, USA.
Article Synopsis
- Recent brain studies indicate that athletes in contact sports experience measurable cognitive and sensory impairments due to cumulative subconcussive impacts throughout the season.
- This study compares a high-contact group to a low-contact control group and includes both male and female high school athletes, using 231 brain scans over a year.
- Results show that while both genders exhibit similar subconcussive impairments, female athletes respond more significantly overall, indicating the importance of monitoring these changes to improve health outcomes related to repetitive head impacts.
Evaluation of the impact of neurology electronic consults (e-consults): Experiences of a neurology resident clinic in a safety-net hospital.
J Telemed Telecare
August 2024
Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA.
Background And Objectives: Electronic consults (e-consults) are asynchronous, formalized requests by a provider to involve a specialist to assist with decision making. E-consults are an alternative to face-to-face consultation and are a promising strategy to efficiently address certain requests for advice. The objective of this project was to examine the utility and characteristics of electronic consults utilized in a safety-net hospital outpatient neurology clinic.
View Article and Find Full Text PDFPrenatal Exposure to Valproic Acid Across Various Indications for Use.
JAMA Netw Open
May 2024
Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville.
Article Synopsis
- Teratogenic risks linked to valproic acid use are significant for women of childbearing age, prompting regulatory agencies to enhance warnings and risk reduction strategies for pregnant individuals.
- The study aimed to assess the pregnancy rates of women using valproic acid alongside contraception, utilizing data from a comprehensive commercial claims database spanning from 2005 to 2020.
- Findings revealed stable pregnancy rates during valproic acid treatment, with mood disorders as the most common indication for its use, while the overall incidence of pregnancy showed little change over the years.
Background: The present study evaluated the long-term safety and tolerability of rimegepant, an orally administered small molecule calcitonin gene-related peptide receptor antagonist, in people with migraine.
Methods: This multicenter, long-term, open-label safety study included adults (≥18 years) with ≥1 year history of migraine who were sequentially enrolled into three groups: participants in the first two groups had either 2-8 or 9-14 moderate to severe migraine attacks per month by history and treated as needed ( [PRN]) with one rimegepant 75 mg oral tablet up to once per calendar day for 52 weeks (PRN 2-8 and PRN 9-14); a third group, included to collect safety data during higher-frequency dosing, had 4-14 moderate to severe migraine attacks per month by history and who took one rimegepant tablet every other day as scheduled dosing plus PRN dosing of one rimegepant tablet for migraine attacks of any severity on nonscheduled dosing days for 12 weeks (every other day (EOD) + PRN).
Results: Overall, 1800 participants self-administered rimegepant (PRN 2-8: n = 1033; PRN 9-14: n = 481; EOD + PRN: n = 286).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!